A binational registry of adults with pulmonary arterial hypertension complicating congenital heart disease

Internal Medicine Journal

Volumn 45, Issue 9, 2015, Pages 944-950

  Strange, G ^a,b,c   Rose, M ^d   Kermeen, F ^e   O'Donnell, C ^f   Keogh, A ^g   Kotlyar, E ^g   Grigg, L ^h   Bullock, A ⁱ   Disney, P ^j   Dwyer, N ^k   Whitford, H ^l   Tanous, D ^m   Frampton, C ⁿ   Weintraub, R ^c,d   Celermajer, D S ^o  

^a UNIVERSITY OF NOTRE DAME   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c Pulmonary Hypertensions Society ANZ Inc   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^h ROYAL CHILDREN'S HOSPITAL   (Australia)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j ALFRED HOSPITAL   (Australia)

^k THE PRINCE CHARLES HOSPITAL   (Australia)

^l ROYAL ADELAIDE HOSPITAL   (Australia)

^m ROYAL HOBART HOSPITAL   (Australia)

ⁿ AUCKLAND CITY HOSPITAL   (New Zealand)

^o UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

Congenital heart disease; PAH; Pulmonary arterial hypertension

Indexed keywords

ACETYLSALICYLIC ACID; AMBRISENTAN; BOSENTAN; DIGOXIN; PROSTACYCLIN; SILDENAFIL; WARFARIN; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; AUSTRALIA AND NEW ZEALAND; CONGENITAL HEART DISEASE; DISEASE REGISTRY; FEMALE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; AUSTRALIA; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; HEART DEFECTS, CONGENITAL; HYPERTENSION, PULMONARY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEW ZEALAND; PATHOPHYSIOLOGY; QUALITY OF LIFE; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; COMBINED MODALITY THERAPY; DIURETICS; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MALE; NEW ZEALAND; QUALITY OF LIFE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84940536978     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12821     Document Type: Article

References (25)

1. van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJ. The changing epidemiology of congenital heart disease. Nat Rev Cardiol 2011; 8: 50-60.
2. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115: 163-172.
3. Marelli AJ, Gurvitz M. From numbers to guidelines. Prog Cardiovasc Dis 2011; 53: 239-246.
4. Schuuring MJ, Vis JC, Duffels MG, Bouma BJ, Mulder BJ. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag 2010; 6: 359-366.
5. Duffels MG, Engelfriet PM, Berger RM, van Loon RL, Hoendermis E, Vriend JW etal. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198-204.
6. Engelfriet PM, Duffels MG, Moller T, Boersma E, Tijssen JG, Thaulow E etal. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93: 682-687.
7. Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58: 538-546.
8. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J 2014; 35: 691-700.
9. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA etal. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
10. Kaemmerer H, Gorenflo M, Hoeper M, Huscher D, Ewert P, Pittrow D. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation]. Dtsch Med Wochenschr 2013; 138: 1247-1252.
11. Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol 2014; 113: 147-155.
12. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014; 35: 716-724.
13. Rose ML, Strange G, King I, Arnup S, Vidmar S, O'Donnell C etal. Congenital heart disease-associated pulmonary arterial hypertension: preliminary results from a novel registry. Intern Med J 2012; 42: 874-879.
14. Wray J, Frigiola A, Bull C, Adult Congenital Heart disease Research Network (ACoRN). Loss to specialist follow-up in congenital heart disease; out of sight, out of mind. Heart 2013; 99: 485-490.
15. Gatzoulis MA, Barst R, Fineman J, Galiè N. Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease. Curr Med Res Opin 2007; 23: S19-25.
16. Keogh A, Strange G, Kotlyar E, Williams T, Kilpatrick D, Macdonald P etal. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J 2011; 41: 235-244.
17. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW etal. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 2011; 140: 19-26.
18. Wilkens H, Grimminger F, Hoeper M, Stahler G, Ehlken B, Plesnila-Frank C etal. Burden of pulmonary arterial hypertension in Germany. Respir Med 2010; 104: 902-910.
19. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM etal. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
20. Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S etal. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study. Pulm Circ 2013; 3: 89-94.
21. Humbert M, Sitbon O, Yaici A, Montani D, O'Callaghan DS, Jais X etal. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
22. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A etal. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
23. Kotlyar E, Sy R, Keogh AM, Kermeen F, Macdonald PS, Hayward CS etal. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol Young 2006; 16: 268-274.
24. Gatzoulis MA, Beghetti M, Galie N, Granton J, Berger RM, Lauer A etal. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; 127: 27-32.
25. Kermeen FD, Franks C, O'Brien K, Seale H, Hall K, McNeil K etal. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart Lung Circ 2010; 19: 595-600.